FDA “Material Time, Material Extent” May Be Cloudy For Sunscreens
This article was originally published in The Rose Sheet
Executive Summary
Interim marketing for OTC drugs or "conditions" in the U.S. subject to a final or new monograph is barred under FDA's final rule on "material time, material extent" criteria